TP53 and neoplasm: Furthermore, deletions and mutations of the tumour suppressors Pten, p53 and Rb are among the most common genomic alterations in human prostate cancer, with two‐thirds of prostate cancers showing alterations in at least one of the three genes (Appendix Fig S1A).